MOLECULAR RESPONSE TO USTEKINUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS BY SERUM PROTEIN AND BIOPSY GENE EXPRESSION ANALYSIS: RESULTS FROM THE UNIFI PHASE 3 INDUCTION STUDY

IL-12 and IL-23 are elevated in ulcerative colitis (UC) and genetic association suggests that they play causative roles in the disease. Ustekinumab (UST) blocks both cytokines and is an effective therapy for moderate-to-severe UC, but its molecular effects in UC patients remain unknown.